Cellectis S.A. (0WA2.L)
| Chiusura precedente | 2,7180 |
| Aperto | 2,6542 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 2,3514 - 2,4300 |
| Intervallo di 52 settimane | 2,3514 - 2,4300 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 2,11 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Mark Frattini, M.D., Ph.D., as Chief Medical Officer, effective immediately. Dr. Frattini has over 20 years of experience in the field of hematological malignancies and joined Cellectis in August 2020 as Senior Vice Preside
- GlobeNewswire
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of votingrights08/31/202245,550,81051,615,672 About CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunothe
- GlobeNewswire
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management plans to participate in four upcoming investor conferences. Details for the events are below: Citi's 17th Annual Biopharma Conference Format: Panel Date: September 7th, 2022 Time: 9:40AM- 10:25AM ETLocation: Four Seasons Hotel
